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Abstract
While the hypothalamo-pituitary-adrenal axis (HPA) activates a general stress response by increasing glucocorticoid (Gc)
synthesis, biological stress resulting from infections triggers the inflammatory response through production of cytokines.
The pituitary gland integrates some of these signals by responding to the pro-inflammatory cytokines IL6 and LIF and to a
negative Gc feedback loop. The present work used whole-genome approaches to define the LIF/STAT3 regulatory network
and to delineate cross-talk between this pathway and Gc action. Genome-wide ChIP-chip identified 3,449 STAT3 binding
sites, whereas 2,396 genes regulated by LIF and/or Gc were found by expression profiling. Surprisingly, LIF on its own
changed expression of only 85 genes but the joint action of LIF and Gc potentiated the expression of more than a thousand
genes. Accordingly, activation of both LIF and Gc pathways also potentiated STAT3 and GR recruitment to many STAT3
targets. Our analyses revealed an unexpected gene cluster that requires both stimuli for delayed activation; 83% of the
genes in this cluster are involved in different cell defense mechanisms. Thus, stressors that trigger both general stress and
inflammatory responses lead to activation of a stereotypic innate cellular defense response.
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Introduction
The pituitary gland is at the center of the hypothalamo-
pituitary-adrenal (HPA) axis that mediates the response to stress
[1,2]. Under normal conditions, the stress response is an integrated
collection of tissue responses that place the organism in a state of
alertness in order to fight or flight in the face of aggression. The
output of the HPA axis during the stress response is exerted by
circulating glucocorticoids (Gc). Indeed, Gc are synthesized by the
adrenals in response to pituitary adrenocorticotropic hormone
(ACTH) which itself is responsive to hypothalamic corticotropin-
releasing hormone (CRH) that integrates neural inputs into this
neuro-endocrine pathway. Gc exert their metabolic effects and a
stress response through action on a wide range of tissues including
liver, muscle and adipose tissues. The metabolic effects of Gc are
profound and failure to maintain Gc levels within the normal
range as in Addison disease (hypocortisolism) results in weight loss,
muscle weakness, fatigue and low blood pressure. Cushing
syndrome is caused by excess Gc and in Cushing disease, this
excess is due to pituitary corticotroph adenomas. Cushing
syndrome is associated with accumulation of body fat, cardiovas-
cular and metabolic effects that can ultimately lead to hyperten-
sion, diabetes and osteoporosis [3]. It is therefore critical that
activation of HPA axis and Gc synthesis be restored to normal
levels following the stress response. Negative feedback is exerted by
Gc themselves both at the level of hypothalamus where they
repress transcription of the CRH gene and release of CRH, and at
the pituitary level where they repress transcription of the pro-
opiomelanocortin (Pomc) gene and the release of POMC-derived
ACTH [1].
The inflammatory response is a response to biological stresses
and various aggressions including those caused by infections [4].
Many effects of the response to inflammation are mediated
through cytokines that act on multiple tissues and importantly on
the HPA axis. Indeed, inflammation-induced cytokines, such as
IL6, stimulate hypothalamic production of CRH and act directly
on pituitary corticotroph cells to stimulate Pomc gene transcription
and ACTH release. LIF, a member of the IL6 family, also
contributes to stimulation of POMC expression, both during
development and in adult function [5]. At the level of pituitary
corticotroph cells, the action of LIF and IL6 are additive with
those of hypothalamic CRH [6]. The HPA axis is thus at the
center of the so-called immuno-neuroendocrine interface [7].
The action of LIF/IL6 in pituitary corticotroph cells was shown
to be mediated in part through activation of STAT3 [8]. STAT3
action on the Pomc promoter was mapped to a composite
regulatory element that also contains the NurRE, a binding site
for dimers of orphan nuclear receptors of the Nur subfamily
[9,10]. The Nur subfamily of orphan nuclear receptors includes
NGFI-B (Nur77), NURR1 and NOR1 [11] and it was shown that
homodimers or heterodimers between members of this subfamily
can activate the NurRE in response to CRH as long as at least one
moiety of the dimers is NGFI-B [12–14]. Thus, a composite
regulatory element integrates LIF/IL6 and CRH signaling.
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Pomc activation by CRH and LIF [15]. Feedback repression of the
Pomc gene by the Gc receptor (GR) is mainly exerted at the level of
the NurRE/Stat3 composite regulatory element [16,17]. GR
repression at the NurRE involves a mechanism of trans-repression
that depends on protein:protein interactions between GR and
NGFI-B, rather than direct GR contact with DNA [16]. Further,
the weak direct interaction between GR and NGFI-B requires the
presence of the Swi/Snf ATPase Brg1 for stable formation of a
trans-repression complex [18]. Brg1 is also required to recruit
HDAC2 to this repressor complex and this repression involves
chromatin remodeling. Thus, the NurRE/Stat3 regulatory
element of the Pomc gene is a critical target for most stimulatory
and inhibitory inputs into this system.
In the present work, we have used whole-genome approaches to
identify STAT3 target sites as revealed by ChIP-chip analysis
using whole-genome tiling arrays [19–21] and to correlate these
with the transcriptome of LIF and Gc responses. These analyses
defined gene clusters that contribute to the repressor effects of Gc
on corticotroph cell function, in particular the inhibitory Gc effect
on cell proliferation. Most interestingly, the work revealed a class
of genes that have delayed responses to LIF+Gc: a large number of
these genes contribute to the cell defense response. Using a highly
LIF- and Gc-dependent gene of this group, lipocalin 2 (Lcn2), we
show synergistic recruitment of STAT3 and GR at a genomic
regulatory module that integrates LIF and Gc responses. Further,
LIF and Gc synergism is exerted on Lcn2 expression and other cell
defense genes in various tissues in vivo and the gene profile of this
action is very similar to that of LPS, a strong inducer of the
inflammatory response. Collectively, this work highlights a general
cell defense response that is dependent on the combined action of
LIF or other cytokines released during inflammatory and immune
responses and Gc produced by the HPA axis. This delayed
stimulatory Gc action likely overlaps with hepatic acute-phase and
innate immune responses [22,23], and it contrasts with the anti-
inflammatory properties of these steroids used therapeutically.
Results
LIF/STAT3 Target Genes
In order to assess the cellular response to LIF/STAT3, the time
course of STAT3 activation in response to LIF in AtT-20 cells, a
model of mouse pituitary corticotroph cells, was determined by
Western blot analysis of phospho-STAT3 (Figure 1A). This
analysis indicated a peak of phospho-STAT3 at about 20 minutes
following LIF treatment. In principle, activated phospho-STAT3
should lead to promoter occupancy of STAT3 target genes and
thus the time course of promoter recruitment was assessed by
chromatin immunoprecipitation (ChIP) in AtT-20 cells for a panel
of STAT3 target genes (Figure 1B). For most of these genes,
maximal promoter occupancy was achieved between 10 and
20 minutes after LIF stimulation.
Genomic targets of LIF activated STAT3 were therefore
identified by ChIP-chip analysis of AtT-20 cells treated with LIF
for 20 minutes. Three independent STAT3 ChIP and control IgG
samples were hybridized on the Affymetrix Mouse Tiling 2.0R
Array Set, covering the entire non-repetitive mouse genome with a
35 bp resolution. The raw data were processed using the MAT
software package [24]. A threshold P value of 10
25 was used to
select peaks of specific STAT3 immunoreactivity throughout the
genome, yielding a calculated false discovery rate (FDR) of 3.3%
[25]. This analysis revealed a total of 3 449 putative STAT3 target
sites in the mouse genome, after removal of 74 sites by redundant
sequence filtering (complete list in Table S1). The chromosomal
distribution of these sites is shown in Figure 1C. The mean length
of genomic regions exhibiting a positive ChIP signal is 804 bp. In
order to test the reliability of those results, 42 genomic sites with P
values ranging from 10
25 to 10
2148 were randomly picked and
STAT3 recruitment at each of these sites was tested on separate
ChIP using QPCR: all 42 tested sites were confirmed to be positive
(Figure 1B–C and data not shown).
STAT3 Binding Sites Preferentially Localize Close to
Transcribed Sequences
The position of STAT3 binding sites on the mouse genome was
analyzed relative to transcription start sites (TSS) of UCSC known
genes. They were mapped either as upstream relative to known
TSS, downstream from known TSS within the gene body or
relative to the 39 end of UCSC known genes (Figure 2A). This
analysis clearly showed a preferential localization of STAT3
binding sites within 5 kb of TSS, with 19.4% of the total site
number within this interval and 9.4% within 1 kb of TSS. Tiling
array data for specific loci previously known to have STAT3
binding sites are also shown in Figure 2. For example, the
promoter region of the Pomc gene is known to have a STAT3
binding site at 2387/2379 bp [8–10], and the tiling array data
show a peak of STAT3 recruitment over this promoter region
(Figure 2B). Similarly, the promoter of the Stat3 gene itself is
known to have a STAT3 binding site, and thus is subject to auto-
regulation. The tiling array shows a peak of STAT3 recruitment
(Figure 2C) that overlaps the reported STAT3 binding site at
2338/2331 bp [26]. The Socs3 gene is involved in negative
feedback regulation of STAT3 signaling and the Socs3 promoter
has a STAT3 binding site at 264/272 bp [27] that overlaps the
observed peak of STAT3 recruitment (Figure 2D). In addition to
these sites, the tiling array data revealed numerous other STAT3
binding sites in the Stat3/Stat5 and Socs3 loci; the biological
relevance of these putative regulatory regions will need to be
evaluated. Interestingly, STAT3 binding sites were found in close
proximity to all Stat genes, except Stat6. Finally, STAT3 binding
sites were found in the vicinity and promoter region of some
Author Summary
Global biological responses involve pleiotropic, general
components exhibited by many cells/tissues together with
cell-specific responses. Typically, such responses are
dependent on multiple signaling pathways that integrate
different inputs to trigger concerted tissue/cell responses.
In studying LIF action in the context of immune-endocrine
regulatory interactions, we found that LIF regulates
expression of a surprisingly small number of genes. In
contrast, the mapping of LIF-activated STAT3 transcription
factor recruitment by genome-wide ChIP-chip led to the
identification of a much larger set of putative regulatory
sites. In view of the cross-talk between cytokine and
glucocorticoid (Gc) signaling in response to stress and
inflammation, we investigated the contribution of Gc to
LIF action. Interestingly, the discrepancy between the
number of LIF-regulated genes and LIF-dependent STAT3
genomic targets was partly explained by widespread Gc
potentiation of LIF action. We further show requirement
on both signaling pathways to elicit a pleiotropic and
stereotypic innate cellular defense response, together with
cell-specific responses such as antagonism between
cytokines and Gc on expression of pituitary POMC. Thus,
this stereotypic innate cell defense response is defined by
the convergence of pathways activated by the stress and
inflammatory systems.
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that was implicated in the STAT3-dependent growth promotion
activity of IL6 [28].
The DNA binding sequence for STAT3 has been defined
experimentally through the work of numerous investigators. For
example, the binding motif used by the Genomatix software to
identify putative STAT3 binding sites is shown in Figure 2F and
compared with a consensus that we derived from 24 published
genomic STAT3 binding sites. We have used two non-biased
algorithms designed to identify recurring motifs within the
STAT3-bound DNA fragments (Figure 1C); the AlignAce
algorithm and the Consensus algorithm identified a consensus
binding motif that is very similar to the previously documented
binding sites for STAT3 (Figure 2F). No other motif was found to
be enriched within the ensemble of STAT3 genomic targets. We
also searched the 3 449 STAT3 target sequences for known
transcription factor binding motifs with MatInspector (Genomatix)
software and again, we found no other enriched motif compared
to 10 randomly picked genomic sequences of the same total length.
Reciprocal Co-Potentiation of STAT3 and GR Recruitment
to Genomic Target Sites
In AtT-20 cells, the stimulatory effect of LIF on Pomc gene
transcription is antagonized by Gc and GR. In order to assess
whether this antagonism is reflected at the level of STAT3 genomic
recruitment, we performed STAT3 ChIP in cells treated either with
LIF, the synthetic Gc dexamethasone (Dex) or both for 20 minutes
and determined STAT3 recruitment by QPCR for a panel of
STAT3 target genes (Figure 3A). While some genes such as Pomc
showed moderately enhanced STAT3 recruitment in response to
LIF+Dex compared to LIF, other genes such as metallothionein 2
(Mt2) revealed marked synergism in STAT3 recruitment in cells
treated with LIF+Dex (Figure 3A). This suggests that recruitment of
one factor potentiates recruitment of the other factor to target
regulatory sequences. About a third of tested genes showed greater
STAT3 recruitment for LIF+Dex compared to LIF treated cells
while another third showed decreased recruitment and the
remaining third showed no effect. In order to assess whether
potentiation of STAT3 recruitment is reciprocal, similar ChIP
analyses were performed for GR recruitment to the same loci and
these analyses again showed potentiation of GR recruitment
following LIF+Dex treatment for the same subset of genes, such
as Pomc and Mt2 (Figure 3B). It is noteworthy that so many
randomly chosen STAT3 target loci are also Gc/GR targets.
Sequential ChIP were performed for STAT3 and GR on three loci
using AtT-20 cells treated with LIF+Dex. These analyses confirmed
that for the Pomc, Mt2 and Lcn2 loci, both GR and STAT3 are
present together on the same chromatin fragments (Figure 3C).
Figure 1. Targets of LIF/STAT3 action. A) The time course of STAT3 activation (phospho- STAT3) was determined in AtT-20 cells following
treatment with LIF (10 ng/ml). Western blot analysis of P-STAT3 is compared to total STAT3 protein. B) Time course of STAT3 occupancy on the
promoter of known STAT3 target genes determined by ChIP and QPCR. C) Chromosomal distribution of genomic binding sites for STAT3 determined
by ChIP-chip analysis of LIF-treated (20 min) AtT-20 cells. Triplicate ChIP samples were analyzed on Affymetrix Mouse Tiling 2.0R Array Sets. Raw data
were extracted with GCOS software (Affymetrix) and were analyzed using the MAT software package. STAT3 enrichment peaks were selected on the
basis of a P value threshold of 10
25. Redundant sequence filtering led to the removal of 74 sequences, thus yielding a final count of 3449 STAT3
binding sites. The list of these sites is presented in Table S1. The tiling array results were validated by QPCR analysis of independent ChIPs for 42 loci
distributed randomly throughout all chromosomes; all 42 were confirmed. The same loci were used for further studies in Figure 3. FDR, calculated
false discovery rate.
doi:10.1371/journal.pgen.1000224.g001
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subject to the combined action of LIF and Gc.
Synergistic Action of LIF and Glucocorticoids
In order to correlate STAT3 genomic binding sites with
regulation by LIF or Gc of adjacent candidate target genes, we
performed expression profiling experiments. Duplicate RNA
samples from AtT-20 cells treated with/without LIF and/or Dex
for 3 h and 18 h were hybridized on Affymetrix MOE expression
arrays. The data were pre-processed using GC-RMA normaliza-
tion within the FlexArray software [29,30]. A total of 2 396
regulated probesets were identified (complete data provided in
Table S2) following a Local-pooled-error test, using a 2-fold
change threshold and a P value smaller than 0.05 [31]. The
number of genes up or down regulated by these treatments is
presented in Figure 4A. Whereas a large number of genes were up
and down regulated by Dex, few genes are affected by LIF (mainly
up regulated). This low number of modulated genes was
unexpected because we identified 3 449 STAT3 binding sites in
presence of LIF. Most significantly, a large number of new genes
are regulated in response to both LIF+Dex, at both 3 h and 18 h
post-treatment (Figure 4C, D). It is noteworthy that early and late
response genes are quite different with a limited number of genes
showing sustained changes of expression at both 3 h and 18 h
(Figure 4B). These data clearly suggest that a class(es) of gene(s) is
dependent on both LIF and Gc for regulation.
In order to correlate LIF regulated genes identified in these
profiling experiments with genomic sites of STAT3 binding
identified by ChIP-chip, we searched for STAT3 binding sites
within 5 or 50 kb of the TSS of hormone responsive genes
(Figure 4E). This analysis showed that 62/42% of LIF regulated
genes have STAT3 binding site within 5 kb of their TSS, and 76/
64% within 50 kb of the TSS, at 3 h/18 h respectively. This
proportion is smaller for Dex and LIF+Dex-regulated genes,
reaching about 30% of genes within 50 kb of TSS. This is higher
than the random expectation value of 18%, calculated for all genes
on the Affymetrix MOE 2.0 microarray.
Cell Response to Stress Is Activated by Joint Action of LIF
and Gc
Clustering analysis using Smooth correlation in the Genespring
GX 7.3 software was performed on the expression profiling data of
hormone-treated AtT-20 cells. A heat map (Figure 5A) of this
clustering identified groups of genes that are similarly regulated
(Figure 5B). Clustering analysis was performed using the Smooth
correlation K means approach. These clusters of co-regulated
genes contain from 77 to 549 probesets (Table S3). The DAVID
software was used to search for over-represented Gene Ontology
(GO) classes of gene functions [32]. Clusters #1, 3, 4 and 8 did not
contain significant numbers of genes associated with similar
biological processes (GO gene lists in Table S4). Cluster #9
regroups genes that are repressed by Dex at both time points: this
cluster contains significant enrichment for genes encoding
transcription and nuclear functions (P#10
25) and cell processes
(P#10
26). Interestingly, cluster #7 is highly enriched in genes
involved in control of cell cycle and mitosis (P#10
214) and these
genes (Figure 5C) are primarily repressed by Dex at 18 h
(Figure 5A and 5B). It is reassuring to find this cell cycle and
mitosis cluster associated with Gc repression since the growth of
AtT-20 cells is known to be inhibited by these steroids [33].
The most striking cluster to be identified in this work is
represented by the 179 probesets of cluster #2 (Figure 5B). These
genes have the particularity of being specifically upregulated at
18 h by the combined action of LIF+Dex, but not by Dex or LIF
alone. Gene Ontology analysis of this cluster reveals a highly
significant (P#10
28) number of genes that are associated with cell
defense response (Figure 5D). To a lower extent, we found other
genes implicated in cell defense response in cluster #5 (Table S4),
which contains the genes activated by LIF at 3 h or 18 h
independently of the presence of Gc. The delayed (18 h) response
of cluster #2 genes is suggestive of a secondary response. In order
to ascertain whether this is the case, we assessed responsiveness to
LIF+Dex of a representative panel of cluster #2 genes in the
presence/absence of the protein synthesis inhibitor cycloheximide
(Figure 5E). This experiment clearly showed that the bulk of this
LIF+Dex response is secondary and dependent on de novo synthesis
of an intermediate regulator(s). Of the genes that are subject to
synergistic activation by LIF+Dex, the Lcn2 gene showed the most
striking potentiation.
Lipocalin 2, a Highly LIF- and Glucocorticoid-Dependent
Gene
In order to validate the great synergism observed between
LIF+Dex effects on Lcn2 mRNA levels in the microarray analyses,
we performed RT-QPCR quantification of Lcn2 mRNA in AtT-20
cells treated for 18 h with either or both agents. These
quantifications indicate that the Lcn2 gene is responsive to LIF
alone (23-fold), highly induced by Dex (10 278-fold), but
phenomenally subject to synergism between these two signals
(156 026-fold) as shown on a log scale in Figure 6A. This striking
upregulation is also revealed by Lcn2 Western blot analysis of
AtT-20 cell culture medium (Figure 6B). No STAT3 binding was
found at the Lcn2 promoter (data not shown), but the STAT3
whole-genome ChIP-chip experiment revealed significant enrich-
Figure 2. STAT3 genomic binding sites. A) Distances between STAT3 binding peaks determined by whole-genome ChIP-chip and nearest known
genes (UCSC mm7 mouse genome assembly). Depending on position relative to the closest gene, data were computed as upstream to nearest TSS
(left), relative to the TSS within the body of the gene itself (middle) or relative to the 39 end of the gene (right). STAT3 binding sites that are outside
these three categories were for the most part intergenic and this group constitutes 21.6% of the total number of STAT3 binding sites identified. B)
Affymetrix Integrated Genome Browser (IGB) representation of tiling array data for STAT3 recruitment at the Pomc locus. In the top diagram, each
vertical line represents the MAT score for one 25 bp oligonucleotide probe; each probe is spaced by 10 bp. The green solid horizontal bar indicates
the interval of statistically significant (P#10
25) STAT3 recruitment. This region contains a documented STAT3 binding site at 2387/2379 bp [8,9]. C)
STAT3 binding sites within the Stat3/Stat5 locus. The upstream region of the Stat3 gene was previously shown to contain an auto-regulatory STAT3
binding site at position 2338/2331 bp [26]. Strong recruitment of STAT3 was observed in this region but also at other positions within the Stat3/
Stat5 locus. Statistically significant peaks (P#10
25) of STAT3 binding are marked by the green boxes under the data diagram for tiling microarray
data. D) Multiple STAT3 binding sites in the Socs3 locus including an upstream site that correlates with the previously documented site at 272/
262 bp [27]. E) STAT3 binding sites flanking a microRNA gene, miR-21. The STAT3 binding peak at 22801 bp is located near a STAT3 binding site
previously identified in human [28]. F) WebLogo representation of known and computed preferred binding site for STAT3. The STAT3 binding site
used by the MatBase database (Genomatix) for in silico analysis is shown together with a binding site derived from analysis of the 24 published
sequences for STAT3 binding. All STAT3 binding regions from the tiling analysis were used to search for redundant DNA motifs, using non-biased
algorithms: Consensus and AlignAce. As shown, both algorithms identified similar motifs. No other motif was identified within this dataset.
doi:10.1371/journal.pgen.1000224.g002
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PLoS Genetics | www.plosgenetics.org 5 October 2008 | Volume 4 | Issue 10 | e1000224Figure 3. Potentiation of STAT3 and GR recruitment at a subset of LIF/STAT3 target genes. A) A group of 32 genomic STAT3 target sites
and 3 control (ctl) loci (Gapdh, Myod and Tbp) were evaluated for STAT3 binding by QPCR analysis of ChIP performed on AtT-20 cells treated for
20 minutes with LIF (10 ng/ml), Dex (10
27 M), both or vehicle. Following analysis, genes were re-grouped for presentation in three classes: those for
which STAT3 recruitment is greater ($1.25 fold) in LIF+Dex than LIF-treated cells and those for which this is equal or smaller. B) GR ChIP performed on
the same loci as for STAT3. C) Sequential ChIPs were performed for three loci on chromatin isolated from AtT-20 cells treated with LIF and Dex to
confirm co-occupancy of STAT3 and GR on the same DNA fragments. Data are shown for single ChIP and for samples immunoprecipitated first with
STAT3 and then GR antibody, and the reverse. In each case, data is presented as fold recruitment relative to the IgG sample and normalized by Gapdh
as QPCR reference.
doi:10.1371/journal.pgen.1000224.g003
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intergenic region (Figure 6C) and no other gene is regulated by
either LIF and/or Dex in the Lcn2 vicinity. In order to assess the
possibility that this STAT3 binding region might represent a
regulatory sequence for Lcn2 expression, we performed analytical
ChIP for STAT3 and GR in this genomic region using cells
Figure 4. Identification of LIF and glucocorticoid regulated genes. A) AtT-20 cells were treated with LIF, Dex, both or vehicle and total RNA
was extracted from cells after 3 h and 18 h of treatment. Affymetrix MOE expression arrays were used to assess expression levels for 45101 probesets
in each condition. The expression profiling data were normalized with the GC-RMA algorithm and statistical analysis was measured by Local-pooled-
error test (LPE). The replicate variance is ,0.001. Changes in gene expression levels in hormone-treated relative to control greater than 2-fold and for
P#0.05 were considered statistically significant. A total of 2396 probesets were thus identified, including all treatment conditions (Table S2). The bar
histogram represents the number of probesets found to be up or down regulated in each condition. B) Bar diagram representing the number of
probesets responding to treatment at either or both time points, for each condition. C–D) Venn diagram showing the overlap of probesets regulated
by LIF, Dex or the combination at 3 h and 18 h of treatment. A large number of probesets were found to be uniquely regulated by both agents. E)
Percentage of hormone regulated genes (probesets) that have at least one STAT3 binding site in the interval between 5 or 50 kb upstream or
downstream of the gene. The random expectation value is calculated on all the genes present on the Affymetrix MOE 2.0 microarray.
doi:10.1371/journal.pgen.1000224.g004
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PLoS Genetics | www.plosgenetics.org 7 October 2008 | Volume 4 | Issue 10 | e1000224Figure 5. Clustering analysis of LIF and Dex regulated genes. A) Heat map representation of gene clustering identified by global analysis of
the expression profiling dataset. The clustering was performed with GeneSpring GX 7.3 using Smooth correlation. B) Box plot representation of
Smooth correlation K-means clustering of hormone regulated genes. The analyses required a minimum of 9 clusters in order to represent the
different subgroups of genes that were found to be significantly associated. The list of genes in each cluster is presented in Table S3. C) Gene
Ontology distribution of genes from cluster #7 that are repressed by Gc at 18 h of treatment, irrespective of the presence of LIF; these genes are
Glucocorticoids Potentiate LIF Action
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potentiation of STAT3 and GR recruitment over this putative
regulatory region (Figure 3A, 3B). Sequential ChIP analyses also
demonstrate STAT3 and GR co-occupancy on this genomic region
(Figure 3C). This 222 kb region may therefore act as a hormone
sensitive enhancer for regulation of Lcn2 expression. In order to test
this hypothesis, a luciferase plasmid reporter was constructed with/
without the putative 1133 bp enhancer domain and assessed for
transcriptional activity upon transfection in AtT-20 cells. This assay
revealed marked transcriptional activity of the putative enhancer
(Figure 6D) and further, the enhancer-containing reporter plasmid
was found to be responsive to LIF, Dex and LIF+Dex treatment
(Figure 6E). Thus, these data clearly suggest that an enhancer is
present at 222 kb upstream of the Lcn2 gene and that this enhancer
is in part responsible for the marked synergistic activation of Lcn2
transcription by LIF+Dex. Notwithstanding the likely involvement
of a cycloheximide-dependent regulator(s) for long term Lcn2
induction (Figure 5E), the data implicate direct actions of STAT3
and GR at the Lcn2 enhancer.
Lcn2 is a secreted protein that is present in blood and its plasma
concentration is greatly enhanced following bacterial challenges
[34,35]. In order to test whether LIF+Dex also stimulate Lcn2
expression in vivo, mice were injected with either LIF, Dex or
LIF+Dex and analyzed for serum Lcn2. The effect of LIF+Dex
was compared to the documented stimulation of Lcn2 expression
by lipopolysaccharides O127:B8 (LPS). While Dex on its own did
Figure 6. Highly synergistic activation of the lipocalin 2 (Lcn2) gene by LIF and glucocorticoids. A) RT-QPCR analysis of Lcn2 mRNA in AtT-
20 cells treated with LIF, Dex or both. Note that the relative mRNA levels are presented on a logarithmic scale. Activation levels relative to control cells
are: LIF (23-fold), Dex (10 278-fold) and LIF+Dex (156 026-fold). B) Western blot analysis of Lcn2 induction in AtT-20 cells treated for various times with
LIF and Dex as indicated. P-STAT3 levels were visualized by Western blot of whole cell extracts (top panel) whereas secreted Lcn2 was revealed by
analysis of culture medium. Lcn2 protein was undetectable in WCE (data not shown). C) Bar representation of STAT3 ChIP-chip data for the Lcn2 locus
from the mouse whole-genome tiling array. The only significant STAT3 recruitment in the vicinity of the Lcn2 gene was observed in an intergenic
region located 22 kb upstream of the Lcn2 gene (red arrow). D) The STAT3 binding region (1133 bp) of the Lcn2 locus was cloned upstream of the
minimal Pomc promoter and assessed for transcriptional activity by transfection into AtT-20 cells. E) The same reporters were assessed for
responsiveness to LIF, Dex and LIF+Dex, as indicated. Only Lcn2 enhancer-containing reporter exhibited hormone responsiveness. Data are presented
as means 6 s.e.m. of three experiments, each performed in duplicates.
doi:10.1371/journal.pgen.1000224.g006
highly enriched (P#10
214–10
211) in cell cycle and mitosis associated functions. The GO gene lists are presented in Table S4. D) Gene Ontology
distribution of cluster #2 genes that are upregulated by the joint action of LIF and Dex at 18 h of treatment. These genes are implicated (P#10
210–
10
24) in cell defense response processes (Table S4). Gene Ontology analyses were made using the DAVID web site [32]. E) RT-QPCR analysis of
randomly selected cluster #2 genes in AtT-20 cells treated with LIF+Dex in presence (LD+CHX) or absence (LD) of the protein synthesis inhibitor
cycloheximide. These genes thus exhibit a secondary protein synthesis-dependent delayed response.
doi:10.1371/journal.pgen.1000224.g005
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to a small increase in serum Lcn2 but the combined LIF+Dex
treatment was even more effective, approaching the response
obtained with LPS injection (Figure 7A). At 20 h of treatment, a
small response to Dex was observed but again the greatest increase
was observed in LIF+Dex treated mice.
Circulating Lcn2 is likely produced by a variety of sources
including liver [34]. It is therefore possible that the synergistic
stimulation of Lcn2 gene expression observed in AtT-20 cells may
be a reflection of a general cellular response to these agents. In
order to test this, RT-QPCR was used to measure Lcn2 mRNA
levels in pituitary and liver of mice injected with LIF, Dex and
LIF+Dex (3 and 20 h), together with a reference group of mice
injected with PBS or LPS (Figure 7B to 7E). These data indicate
that the synergistic action of LIF+Dex is not unique to the
pituitary. Liver production of Lcn2 could thus account for a
Figure 7. In vivo regulation of LIF and glucocorticoids dependent genes. A) Lcn2 serum levels were measured in mice following injection of
LIF (100 mg/kg), Dex (400 mg/kg), or both intraperitoneally at 3 h and 20 h post-treatment. The 20 h group of mice received 5 injections of LIF and/or
Dex respectively, in order to maintain hormone plasma levels. A group of mice were also injected with LPS (100 mg/kg) as positive control. Serum
Lcn2 revealed by Western blot is shown for 2 mice in each group. B) Pituitary Lcn2 mRNA levels were measured by RT-QPCR at 3 h post-treatment in
mice treated with vehicle (C), LIF (L), Dex (D), LIF+Dex (LD) or LPS, as indicated. C) Pituitary Lcn2 mRNA levels at 20 h post-treatment. Note different
scale relative to B. D) Liver Lcn2 mRNA levels assessed by RT-QPCR at 3 h post-treatment. E) Liver Lcn2 mRNA at 20 h post-treatment. F) Genes from
cluster #2 implicated in cell defense mechanisms (GO analysis) were randomly picked and the relative abundance of their mRNA was assessed by RT-
QPCR in pituitary, liver, testis, lung and heart of mice 20 h after injection of vehicle (PBS), LIF+Dex (LD) or LPS. G) LIF and IL6 receptor mRNA levels
relative to b-Actin mRNA as measured by RT-QPCR in untreated AtT-20, 10TK and NIH 3T3 cells. H) Synergistic activation of Lcn2 and three cluster #2
genes by LIF+Dex and IL6+Dex treatment in AtT-20, 10TK and NIH 3T3 cells.
doi:10.1371/journal.pgen.1000224.g007
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with LIF+Dex.
To assess whether the cell defense mechanism activated in AtT-
20 by LIF+Dex (cluster #2) is active and generalized in vivo,w e
randomly selected genes within this cluster. mRNA levels were
measured by RT-QPCR in five tissues (pituitary, liver, testis, lung
and heart) from mice treated for 20 h with PBS, LIF+Dex or LPS.
As above, this experiment was performed in mice that have
normal Gc levels using a pharmacological dose of Dex together
with LIF. In all five tissues, the two treatments produced
comparable patterns of gene activation (Figure 7F). It thus appears
that the cell defense mechanisms activated by LIF+Dex are very
similar to those activated by LPS, in agreement with the
stimulatory effect of LPS on cytokines, ACTH and Gc [36].
Many genes synergistically activated by LIF+Dex are part of the
hepatic acute-phase and innate immune response [22,23].
In view of this widespread in vivo response, we verified whether
similar responses would be observed in cell lines other than AtT-
20. Furthermore, we tested the responses to the LIF-related
cytokine IL6 that is also induced during the inflammatory
response. We used the 10TK cells that co-express the LIF and
IL6 receptors, like AtT-20 cells, but also the NIH 3T3 cells that
only express the IL6 receptor, as shown by RT-QPCR (Figure 7G).
These analyses showed LIF+Dex as well as IL6+Dex synergism in
all three cell lines (Figure 7H).
Discussion
The present work was undertaken to define the action of LIF
and related cytokines such as IL6 on corticotroph function in the
context of immuno-neuroendocrine interactions. Surprisingly, LIF
signaling on its own was found to modulate a very limited gene
subset. Indeed, most LIF-regulated genes are similarly activated at
3 h and 18 h, they are found in cluster #5 (77 probesets
representing 57 unique genes) and many have been involved in
corticotroph signaling and Pomc transcription, such as Jak3, Stat1,
Stat3, Socs3, Junb, c-Fos, Cebpd (Table S3). The majority of these
genes recruit STAT3 close to their TSS (Figure 4E) and they
contain a canonical STAT3 binding site (Figure 2F). Collectively,
they define a pathway for LIF/STAT3-dependent activation of
transcription but the small number of genes involved contrasts
with the much larger number of genomic STAT3 recruitment sites
(Figure 1C). This discrepancy is largely explained by the great
number of LIF-sensitive genes that are potentiated by Gc
(Figure 4). In contrast to LIF, Gc on their own affect a large
number of genes, consistent with other genomic studies of Gc
action [37,38]. Many of these genes respond transiently to Dex
either at 3 h (cluster #4 genes are activated, cluster #9 repressed)
or at 18 h (cluster #1 genes are activated and #7 repressed) but
other gene clusters exhibit sustained changes in expression
(activation for cluster #3 and repression for cluster #6). But the
most interesting gene clusters to arise from this analysis show
delayed (18 h) responses that require both Dex and LIF (cluster
#2 for activated genes, cluster #8 for repressed genes). In
particular, cluster #2 is enriched in genes involved in different
cellular responses to aggression or stress, including genes that are
part of the innate immune response and of the hepatic acute-phase
response.
Mechanism of STAT3 Action
The mapping of STAT3 binding sites on the mouse genome in
LIF-stimulated cells identified 3 449 high confidence sites
(Figure 1). This number stands in stark contrast with the relatively
limited number of LIF-regulated mRNAs identified in profiling
experiments (Figure 4). Although it is possible that a large number
of target genes are regulated less than the 2-fold threshold of
expression profiling data, it is more likely that this small number of
LIF-regulated genes reflects the dependence of STAT3 on other
transcription factors for activity. This action includes a moderate
stimulatory effect on Pomc gene expression: within the context of
Pomc regulation, LIF action is mostly meaningful in association
with the stimulatory action of CRH signaling and the downstream
Nur orphan nuclear receptors [10].
Nonetheless, it appears that activation of STAT3 by phosphor-
ylation (Figure 1A) leads to promoter occupancy of a large number
of target genes (Figure 1B, 1C), independently of other signaling
pathways. These STAT3 targets include cell-specific genes such as
Pomc (Figure 2B) and genes involved in STAT3 signaling itself
(Figure 2C, 2D). The STAT3 target genes defined through ChIP-
chip analysis also include a large number of genes that are co-
regulated by Gc. Independently of this co-regulation, non-biased
analysis of STAT3 genomic binding regions only revealed one
conserved sequence motif, the STAT3 binding site itself
(Figure 2F). This conserved motif is entirely consistent with the
previously defined STAT3 binding site [27,39]. It is noteworthy
that this analysis did not reveal enrichment of any other motif: it
might have been expected that some transcription factor binding
motifs might have been enriched in association with STAT3
targets since STAT3 has already been shown to act in association
with a variety of factors including GR [40]. Failure to detect
particular enrichment of one binding motif with STAT3 binding
sites may reflect the fact that STAT3 binding sites is associated
with a large array of conserved binding motifs for many structural
classes of DNA binding proteins and/or that these other factors act
by protein:protein interactions with STAT3. The localization of
binding peaks within STAT3 binding regions corresponded quite
closely to the position of known STAT3 binding sites (Figure 2B to
2E). For example in the Pomc promoter (Figure 2B), a binding peak
was observed at 2465 bp whereas the published STAT3 binding
site is located at 2387/2379 bp [8–10].
Potentiation of LIF Action by Gc
A surprising finding of this study has been the large number of
genes that exhibit potentiation of LIF effects (activation or
repression) by Gc (cluster #1, 2, 7 and 8). The Venn diagrams
(Figure 4C and 4D) clearly illustrate the large number of genes
that are subject to Gc potentiation of LIF activity. Interestingly, a
similar proportion (about 2/3) of randomly chosen STAT3-
binding loci showed enhancement or antagonism of STAT3
recruitment in presence of LIF+Dex compared to LIF alone
(Figure 3A). Also, many of these loci showed enhanced GR
recruitment in LIF+Dex compared to Dex-treated cells (Figure 3B).
The potentiation of GR recruitment to STAT3 loci may involve
direct protein interactions between these effectors as such
interactions have been documented [41]. Direct STAT3:GR
interactions may cause transcriptional synergism [41] but they
may also reflect transcriptional antagonism as observed for trans-
repression of LIF and/or CRH-induced Pomc transcription by GR.
Indeed, Gc repress Pomc transcription without direct DNA binding
by GR: the present work showed enhanced GR and STAT3
recruitment to the Pomc promoter in Dex+LIF-treated cells
compared to Dex or LIF alone (Figure 3A, B) and we have
similarly showed enhanced NGFI-B and GR recruitment to this
promoter in CRH+Dex-treated cells compared to either treatment
[18]. The potentiation of genomic recruitment of one factor by
another is thus a clear indication of transcriptional interactions,
but it does not predict whether an interaction may be synergistic
or antagonistic on transcription.
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In addition to its repressor effect on Pomc transcription [42], Gc
inhibit the growth of AtT-20 cells [33]. Cluster #7 genes are
repressed by Dex at 18 h but not 3 h irrespective of the presence
of LIF and it is enriched in genes involved in cell cycle control and
mitosis (Figure 5A–C). This gene cluster therefore contains the
ensemble of gene functions that may work coordinately to repress
cell proliferation. It will be interesting to assess whether a similar
group of genes is also involved in the growth inhibitory effects of
Gc on immune or other cells.
The Cell Defense Response
A unique cluster of genes was identified in the present work and
is represented by cluster #2 (Figure 5D). This 179 probesets (150
genes) cluster is highly enriched in genes involved in cell defense
response. Upon removal of 40 genes of unknown function, the
remaining 110 genes with known or suspected function were
queried for involvement in various processes. Of these, a total of
91 genes were previously associated with various cell defense
mechanisms, such as innate responses to viruses or to bacteria, or
acute phase response. This group thus represents 83% of genes
with documented function in cluster #2. The group includes genes
of the innate response to viral infection that are interferon induced
(ISGs) [43]: examples of this group include the six 29-59-
oligoadenylate synthetase (Oas) genes, the Mx1 and Mx2 genes,
Irf7 and Pkr (Figure S1). Interestingly, the interferon genes
themselves and Toll-like receptors were not induced by LIF+Dex.
Similarly, the bacterial infection and acute phase response genes
[44,45] Tpl2, Saa3, Haptoglobin and Serpina3 were all found in
cluster #2 but the a2-macroglobulin gene was not. It should be
mentioned however that other ISGs and cell defense genes were
induced in these experiments under different regulatory modalities
and therefore they are found in clusters other than #2. The genes
of cluster #2 thus represent an innate defense mechanism that is
triggered by joint activation of the inflammatory response and
HPA axis. This innate cell defense response may be evolutionary
conserved as it has been suggested for the functions of Mx and Oas
genes [46,47].
The most striking example of a LIF+Dex-dependent gene is Lcn2
that is induced more than 150 000-fold in AtT-20 cells (Figure 6A).
Whereas the Lcn2 promoter does not exhibit any STAT3 or GR
recruitment (Figure 6C and data not shown), their activities are
likely conferred, at least in part, upon the Lcn2 gene by a putative
enhancer element identified 22 kb upstream of the Lcn2 gene
(Figure 6C–E). Interestingly, the putative Lcn2 enhancer exhibits
potentiation of GR binding upon LIF/STAT3 action and the
reverse (Figure 3). However, it is clear that direct action of STAT3
and GR on the Lcn2 locus is not the only mechanism of activation
since at 18 h post-stimulation, most of the response to LIF+Dex is
dependent on de novo protein synthesis (Figure 5E). In fact, most of
cluster #2 genes exhibit an analogous secondary response.
Lcn2 regulation thus exemplifies a cell defense response that
appears to be shared by many cells and tissues [48,49]. We have
ascertained this in vivo by injection of LIF, Dex, or both in normal
mice and compared these responses with LPS challenge in
pituitary and liver. Lcn2 expression was induced by LIF in both
tissues and Dex treatment exerted synergistic activation at 3 h
post-treatment (Figure 7A–E). Less synergism of Dex action with
LIF was observed in vivo compared to tissue culture cells
(Figure 6A), but the in vivo experiments were conducted in mice
with normal adrenal function and Gc levels.
In order to test the responsiveness of cluster #2 genes in various
tissues in vivo, a similar experiment was conducted in mice injected
with LIF+Dex compared to LPS-injected animals. As shown
graphically in Figure 7F, the response patterns to these agents are
similar in five tissues. It is noteworthy that tissues not usually
associated with the acute phase response, share this response
pattern. These conclusions are also supported by experiments
using different cell lines (Figure 7G and 7H). Thus, LIF/IL6 and
Gc appear to elicit an innate cell defense response. With regards to
Gc, this positive action has been interpreted as pro-inflammatory
[22] but it may be more appropriately interpreted as a local cell
defense response that is distinct and complementary to the
systemic anti-inflammatory actions of Gc. It is interesting to
suggest that the innate cell defense response identified in the
present work may constitute an ancestral defense mechanism.
Materials and Methods
Cell Culture and Transfection
AtT-20 cells were maintained in DMEM supplemented with 10%
fetal bovine serum and antibiotics. The cells were transfected with
500 ng of luciferase reporter construct using Lipofectamine reagent
(Invitrogen). The following day, cells were stimulated for 4 h with
either PBS as vehicle, LIF 10 ng/ml (Chemicon), dexamethasone
(Dex) 10
27 M (Sigma), or a combination of LIF+Dex.
Western Blots
Whole cell extracts (WCE) were prepared and analyzed on
SDS-PAGE as described [18]. Western blots were revealed using
STAT3 (sc-482), phospho-STAT3 (sc-7993), a-Tubulin (sc-32293)
and Lcn2 (sc-50351) antibodies from Santa Cruz Biotechnology.
Chromatin Immunoprecipitation (ChIP), Sequential ChIP
and QPCR
AtT-20 cells were grown to 60–70% confluence and stimulated
with 10 ng/ml LIF and/or 10
27 M Dex for 20 min. ChIP were
performed as described previously [50], with little modifications.
Briefly, chromatin was crosslinked with 1% formaldehyde added
directly to the culture medium (5 min at room temperature).
Crosslinking was stopped with glycine 125 mM in PBS for 5 min,
followed by chromatin preparation. Sonicated chromatin was
immunoprecipitated with either rabbit IgG (Sigma G2018), GR
(sc-1004) or a combination of phospho-STAT3 (sc-7993) and
STAT3 (sc-482) antibodies and collected using protein-A/G beads
(Santa Cruz Biotechnologies). After washes and decrosslinking,
DNA was purified using QIAquick columns following manufac-
turer’s directives. For sequential ChIP, chromatin immunoprecip-
itates were gently eluted with elution buffer (10 mM Tris-HCl
pH8, 1% SDS) for 20 min at 65uC. Supernatants were diluted to
0.5% SDS, 0.5% Triton, 0.05% NaDOC, 10 mM Tris-HCl pH8
and 140 mM NaCl, and complemented with 0.5 mg/ml BSA,
0.05 mg/ml yeast tRNA and 0.025 mg/ml phage l DNA. The
second immunoprecipitation was performed as described above
for single ChIP. Enrichment was assed by QPCR with Qiagen
QuantiTect SYBR green PCR kit. The list of oligonucleotides
used is available upon request.
Whole-Genome Tiling Arrays
Three independent STAT3 and control IgG ChIP samples were
amplified, fragmented, biotin labeled and hybridized on Affymetrix
Mouse Tiling 2.0R Array Set as recommended by the company.
Raw data were processed with the MAT software [24] to calculate
peak intensity and determine statistically significant enrichment of
specific genomic regions. A P value cut-off of 10
25 was applied and
redundant sequences were subtracted following BLAT search.
Thus, the STAT3 whole-genome ChIP-chip yielded 3 449 sites
with a predicted false discovery rate (FDR) of 3.3%.
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De novo motif analyses were done using two different sequence
alignment algorithms. First, 800 bp masked sequences were
retrieved from UCSC genome browser for each of the STAT3
binding sites: those included 400 bp upstream and downstream of
MAT defined enrichment peaks. These sequences were processed
using AlignAce [51] and Consensus [52]. The graphical
representation of the position weight matrices obtained from
these analyses were generated with WebLogo [53].
The same sequence set was challenged against all known
transcription factor binding motifs using the MatInspector
software (Genomatix). The resulting occurrence of each motif
was compared to the mean number of predicted binding sites in 10
randomly picked genomic sequence sets.
RNA and Expression Arrays
Total RNA was extracted from AtT-20 cells previously treated
for 3 or 18 h with vehicle, 10 ng/ml LIF and/or 10
27 M Dex,
using RNeasy columns (Qiagen). Two biological replicates of each
condition were hybridized on Affymetrix MOE 430 2.0 arrays,
except for Dex 18 h that was hybridized on the previous version of
MOE A and B arrays. Hybridization and scanning were done at
the McGill University and Genome Que ´bec Innovation Centre.
Data were normalized using GC-RMA [29,30] on the FlexArray
application. The variance between replicates is smaller than 0.001.
We used the Local-pooled-error test (LPE) to assess differential
gene expression between control and hormone treated cells [31].
Gene expression with fold changes greater than 2 (P#0.05) were
considered significant.
Genes from cluster #2 were picked randomly for RT-QPCR
validation. AtT-20 cells were treated with LIF+Dex (10 ng/ml and
10
27 M respectively) in presence or absence of cycloheximide at
10 mg/ml (Sigma). We also treated AtT-20, 10TK and NIH 3T3
cells with LIF (10 ng/ml), IL6 (10 ng/ml), Dex 10
27 M alone or
in combination for 18 h. Total RNA was extracted as described
above and gene expression was quantified with the Qiagen
OneStep RT-QPCR kit.
Clustering and Gene Ontology Analysis
The genes with expression changes in at least one condition
(LIF, Dex, LIF+Dex, at 3 h or 18 h) were uploaded into
GeneSpring GX 7.3 software (Agilent) for analysis. Smooth
correlation was used to do unbiased clustering. Following this,
K-mean clustering using Smooth correlation was used to separate
genes with the same expression reactivity. We determined that 9
clusters is the most segregating setting for our dataset. The gene
lists extracted from those 9 clusters were uploaded into the
DAVID website [32] to search for enriched biological processes.
The Affymetrix MOE 430 2.0 gene list was used as reference.
Thresholds were set at a minimum of 5 genes per Gene Ontology
class and a P value # 0.001.
In Vivo Experiments
Groups of six CD1 male mice aged between 10 and 14 weeks
were injected intraperitoneally with either PBS, 100 mg/kg LIF,
400 mg/kg Dex, LIF+Dex or 100 mg/kg LPS (O127:B8, Sigma)
and sacrificed after 3 h. Similar groups were sacrificed at 20 h
following 5 injections, except for LPS (only one LPS injection and
4 PBS injections). Mice were anaesthetized with 0.025 ml/g of
avertin 2.5%. 1 ml of blood was collected by cardiac puncture.
Serum proteins (100 mg) were loaded onto SDS-PAGE and Lcn2
protein was revealed by Western blot. Lcn2 is a small 26 kDa
protein and the upper part of gels was stained with Coomassie blue
as loading control. Pituitary, liver, testis, lung and heart were
dissected out following sacrifice. Total RNA was extracted from
these tissues using RNeasy column as described by Qiagen. cDNA
was produced using SuperScript III (Invitrogen) and gene
expression was measured by QPCR with Qiagen QuantiTect
SYBR green. Lcn2 and other mRNA levels were normalized in
respect to b-actin mRNA. The oligos sequences are available upon
request. Animal experimentation was approved by the IRCM
Animal Care and Use Committee, in conformity with regulations
of the Canadian Council on Animal Care.
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